1st Quarter - Report

VERTEX PHARMACEUTICALS INCORPORATED for VERTEX PHARMACEUTICALS INCORPORATED

Firm
Client
Income
—
Expenses
$410,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Issues related to corporate tax law and international tax policies (no specific bills).

LobbyistCovered position, as disclosed
SCOTT BARNES —
SAMANTHA VENTIMIGLIA —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS)

Health Issues HCR

Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills); Issues related to the development and application of gene and cell therapies (no specific bills); Issues related to health care cost and price transparency (no specific bills).

LobbyistCovered position, as disclosed
SCOTT BARNES —
MATTHEW O SCHUMAKER —
SAMANTHA VENTIMIGLIA —

Contacted: Health & Human Services, Dept of (HHS); SENATE; HOUSE OF REPRESENTATIVES

Medicare/Medicaid MMM

Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).

LobbyistCovered position, as disclosed
SCOTT BARNES —
MATTHEW O SCHUMAKER —
SAMANTHA VENTIMIGLIA —

Contacted: SENATE; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.